

# Exploring the use of routine data for recruitment and follow-up in large randomised trials

Danielle Edwards

# Overview

- About me
- Why use routine data?
- Recruitment using routine data
- Follow-up using routine data
- Complications/Issues
- Conclusions

# About me

- Medical statistician
- MRC HTMR funded D.Phil. at Oxford University
  - Using data from two cardiovascular disease trials, investigated recruitment and follow-up using routine data
  - Two systematic reviews: one looking at using routine data for recruitment, one using routine data for follow-up
- Currently working at Imperial College London in Cystic Fibrosis research – linkage of registry data with HES



# Why use routine data?

- Recruitment into trials can be difficult
  - Many don't recruit to target
  - Or need extensions to recruit enough participants
- A study of MRC/HTA funded trials found<sup>1</sup>:
  - Only 31% achieved/passed their target recruitment
  - ~45% trials failed to reach 80% of their recruitment target

# Why use routine data?

- Issues with recruitment:
  - Difficult to recruit enough patients
  - Lengthy process to recruit patients
  - Screened > Eligible > Consented
- Issues with follow-up:
  - Follow-up is expensive
  - Loss to follow-up
  - Adjudication is time-consuming



# Systematic review: Recruitment using routine data

243 abstracts  
screened



36 papers full  
text assessed



15 studies for  
synthesis

## **Types of routine data used for recruitment:**

67% (n=10) solely used routine data for recruitment.

81% (n=13) used electronic health records alone

Other types included insurance databases & research databases

8 used primary care/GP records

2 used electronic hospital records

6 used USA healthcare systems

2 used insurance databases



# Systematic review: Recruitment using routine data

243 abstracts  
screened



36 papers full  
text assessed



15 studies for  
synthesis

## Disease area of RCT:

- Five of the trials were looking at cardiovascular disease outcomes
- Four were looking at diabetes outcomes
- Two were looking at respiratory outcomes
- Two were looking at arthritis outcomes
- There were also studies that looked at neurological outcomes, kidney disease, mental health, drug abuse, general health, and other common chronic diseases



# Systematic review: Recruitment using routine data

243 abstracts  
screened



36 papers full  
text assessed



15 studies for  
synthesis

## Recruitment strategy

- Most of the studies in this review used routine database searches as their only recruitment method
- Six of the studies used routine data searches alongside other recruitment methods.





# Systematic review: Recruitment using routine data

243 abstracts  
screened



36 papers full  
text assessed



15 studies for  
synthesis

## Sample size

- Smallest trial, n = 29
- Largest trial, n = 9250
- Largest trials used routine data along with other methods



# Introduction to the trials

- Two large cardiovascular disease trials
- The Heart Protection Study (HPS)
- The REVEAL trial
- Both trials were investigating the effects of lipid-modifying treatment among people at increased risk of cardiovascular disease
- Potentially eligible patients were identified from hospital records
  - List of the relevant disease codes was sent to each site and the electronic discharge records were searched for patients with these codes.
  - Further information was then sought and with the permission of their doctors, patients were invited by CTSU to attend a screening appointment for the trial.




# Heart Protection Study (HPS)

Patients at high risk of vascular disease

Daily simvastatin 40mg/matching placebo

Daily antioxidant vitamin supplements/matching placebo




# REVEAL (UK patients)





Patients with pre-existing vascular disease

Daily atorvastatin (20mg/80mg)

Daily anacetrapib 100mg/matching placebo



# Decline in trial uptake

Trial	Years recruiting	Invited	Screened	Randomised
	1994-1997	130 457	48.8%	15.7%
	1998-2001	83 237	41.8%	14.5%
	2007-2010	230 000	10.4%	3.5%
	2011-2013	336 490	5.7%	2.5%

# Systematic review: Follow-up using routine data

1198 abstracts  
screened



46 papers full  
text assessed



23 studies for  
synthesis

## Types of routine data used for recruitment:

37% (n=10) solely used routine data for recruitment

Others used a combination of:

- Telephone follow-up

- Interviews & questionnaires

- Pharmacy data

- Billing records

- Mailed questionnaires



# Systematic review: Follow-up using routine data

1198 abstracts  
screened



46 papers full  
text assessed



23 studies for  
synthesis

## **Disease area of RCT:**

Cardiovascular disease outcomes, n=7

Diabetes outcomes, n=3

Psychiatric outcomes, n=3

Cancer-related outcomes, n=2

Respiratory outcomes, n=2

Others include trauma, vaccinations, transplantation, obesity, orthopaedics, daily functioning, and occupational health



# Systematic review: Follow-up using routine data

1198 abstracts  
screened



46 papers full  
text assessed



23 studies for  
synthesis

## Sample size:

Smallest, n=68

Largest, n=88 150

Median (IQR): 1004 (468-4844)

Largest studies (n>10 000) all used routine data alone





# Systematic review: Follow-up using routine data

1198 abstracts  
screened



46 papers full  
text assessed



23 studies for  
synthesis

## Length of follow-up:

Shortest, = 7 days

Longest = 10 years


Median (IQR): 1 year (202.5-543.7)



# Follow-up using routine data

June 1994

Nov 2001



**Recruitment** Jun 1994 – May 1997



**Follow-up (in-trial)** Until Nov 2001



**HES Data available** Apr 97 - Nov 2001 +

# Follow-up using routine data

\*Slides containing the forest plots comparing trial outcomes to those recorded in HES data have been removed – will be made accessible after publication



# Complications & issues

- Can be difficult to access routine data
- Not in real time
- Wouldn't work for safety monitoring in-trial
- Dependent on trial outcomes



# Conclusions

- Routine data can be used as an efficient way to recruit patients to clinical trials
- Publications should include more details on methodology – consider separate methods paper
- HES data can be used to accurately capture cardiovascular outcomes
- Delays in accessing HES may mean that it is not suitable for a means of follow-up in some trials

Thank you



Any questions?



danielle.k.edwards@gmail.com